Cargando…

Will the Interactions of Some Platinum (II)-Based Drugs with B-Vitamins Reduce Their Therapeutic Effect in Cancer Patients? Comparison of Chemotherapeutic Agents such as Cisplatin, Carboplatin and Oxaliplatin—A Review

Pt (II) derivatives show anti-cancer activity by interacting with nucleobases of DNA, thus causing some spontaneous and non-spontaneous reactions. As a result, mono- and diaqua products are formed which further undergo complexation with guanine or adenine. Consequently, many processes are triggered,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Szefler, Beata, Czeleń, Przemysław
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862491/ https://www.ncbi.nlm.nih.gov/pubmed/36675064 http://dx.doi.org/10.3390/ijms24021548

Ejemplares similares

The Affinity of Carboplatin to B-Vitamins and Nucleobases
por: Szefler, Beata, et al.
Publicado: (2021)

Affinities to Oxaliplatin: Vitamins from B Group vs. Nucleobases
por: Szefler, Beata, et al.
Publicado: (2022)

Molecular dynamics study of the inhibitory effects of ChEMBL474807 on the enzymes GSK-3β and CDK-2
por: Czeleń, Przemysław, et al.
Publicado: (2015)

Potential inhibitory effect of indolizine derivatives on the two enzymes: nicotinamide phosphoribosyltransferase and beta lactamase, a molecular dynamics study
por: Szefler, Beata, et al.
Publicado: (2017)

The Oxindole Derivatives, New Promising GSK-3β Inhibitors as One of the Potential Treatments for Alzheimer’s Disease—A Molecular Dynamics Approach
por: Czeleń, Przemysław, et al.
Publicado: (2021)

Designing and Synthesis of New Isatin Derivatives as Potential CDK2 Inhibitors
por: Czeleń, Przemysław, et al.
Publicado: (2022)

ADMET and Solubility Analysis of New 5-Nitroisatine-Based Inhibitors of CDK2 Enzymes
por: Czeleń, Przemysław, et al.
Publicado: (2023)

Characterization in Dual Activation by Oxaliplatin, a Platinum-Based Chemotherapeutic Agent of Hyperpolarization-Activated Cation and Electroporation-Induced Currents
por: Chang, Wei-Ting, et al.
Publicado: (2020)

Long-term platinum retention after treatment with cisplatin and oxaliplatin
por: Brouwers, Elke EM, et al.
Publicado: (2008)

Ototoxicity and Platinum Uptake Following Cyclic Administration of Platinum-Based Chemotherapeutic Agents
por: Gersten, Benjamin K., et al.
Publicado: (2020)

The influence of acute kidney disease on the clinical outcomes of patients who received cisplatin, carboplatin, and oxaliplatin
por: Fernandes, Alexandre Ricardo Da Silva, et al.
Publicado: (2022)

New Perfluorophtalate Complexes of Platinum(II) With Chemotherapeutic Potential
por: de Oliveira, M. B., et al.
Publicado: (1996)

Comparison of Renal Functions Evaluated by Measured Glomerular Filtration Rate in Patients Treated With Cisplatin, Carboplatin, and Oxaliplatin
por: Choudhary, Rajnee, et al.
Publicado: (2023)

Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
por: Peng, B., et al.
Publicado: (1997)

Role of the DNA Base Excision Repair Protein, APE1 in Cisplatin, Oxaliplatin, or Carboplatin Induced Sensory Neuropathy
por: Kelley, Mark R., et al.
Publicado: (2014)

Impact of chemotherapeutic agents on liver microenvironment: oxaliplatin create a pro-metastatic landscape
por: Ma, Yuanyuan, et al.
Publicado: (2023)

Genetic and cellular sensitivity of Caenorhabditis elegans to the chemotherapeutic agent cisplatin
por: García-Rodríguez, Francisco Javier, et al.
Publicado: (2018)

Oxaliplatin-Based Doublets Versus Cisplatin or Carboplatin-Based Doublets in the First-Line Treatment of Advanced Nonsmall Cell Lung Cancer
por: Yu, Jing, et al.
Publicado: (2015)

Carboplatin Plus Vincristine as an Alternative Chemotherapeutic Scheme in Patients With Glioblastoma
por: Sangrador-Deitos, Marcos V, et al.
Publicado: (2022)

Carboplatin and oxaliplatin in sequenced combination with bortezomib in ovarian tumour models
por: Al-Eisawi, Zaynab, et al.
Publicado: (2013)

Therapeutic Potential and Molecular Mechanisms of Emblica officinalis Gaertn in Countering Nephrotoxicity in Rats Induced by the Chemotherapeutic Agent Cisplatin
por: Malik, Salma, et al.
Publicado: (2016)

The Effect of Cucurbit[7]uril on the Antitumor and Immunomodulating Properties of Oxaliplatin and Carboplatin
por: Pashkina, Ekaterina, et al.
Publicado: (2021)

STATing the importance of immune modulation by platinum chemotherapeutics
por: Hato, Stanleyson V., et al.
Publicado: (2012)

Platinum accumulation in oxaliplatin‐induced peripheral neuropathy
por: Wei, Guoli, et al.
Publicado: (2021)

A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer
por: Glasspool, R M, et al.
Publicado: (2014)

Evaluation for Synergistic Effects by Combinations of Photodynamic Therapy (PDT) with Temoporfin (mTHPC) and Pt(II) Complexes Carboplatin, Cisplatin or Oxaliplatin in a Set of Five Human Cancer Cell Lines
por: Lange, Carsten, et al.
Publicado: (2018)

Cisplatin/carboplatin cross-resistance in ovarian cancer.
por: Gore, M. E., et al.
Publicado: (1989)

Monofunctional Platinum(II) Anticancer Agents
por: Jin, Suxing, et al.
Publicado: (2021)

Evaluation of combination protocols of the chemotherapeutic agent FX-9 with azacitidine, dichloroacetic acid, doxorubicin or carboplatin on prostate carcinoma cell lines
por: Weiner, Franziska, et al.
Publicado: (2021)

Evaluation of novel ammine/amine platinum (IV) dicarboxylates in L1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin.
por: Orr, R. M., et al.
Publicado: (1994)

Combination chemotherapy with taxane and platinum in patients with salivary gland carcinoma: a retrospective study of docetaxel plus cisplatin and paclitaxel plus carboplatin
por: Onaga, Ryutaro, et al.
Publicado: (2023)

Cytotoxic effects of the newly-developed chemotherapeutic agents 17-AAG in combination with oxaliplatin and capecitabine in colorectal cancer cell lines
por: Mohammadian, Mahshid, et al.
Publicado: (2017)

A comparative analysis of the mutagenicity of platinum-containing chemotherapeutic agents reveals direct and indirect mutagenic mechanisms
por: Szikriszt, Bernadett, et al.
Publicado: (2021)

Binding of Platinum(II) to Some Biologicaly Important Thiols
por: Petrovic, Biljana V., et al.
Publicado: (1999)

Anti-cancer effects of newly developed chemotherapeutic agent, glycoconjugated palladium (II) complex, against cisplatin-resistant gastric cancer cells
por: Tanaka, Mamoru, et al.
Publicado: (2013)

The Effects of Chemotherapeutic Agents, Bleomycin, Etoposide, and Cisplatin, on Chromatin Remodeling in Male Rat Germ Cells
por: Bagheri-Sereshki, Negar, et al.
Publicado: (2016)

Successful Treatment with Pemetrexed, Carboplatin, and Bevacizumab for Platinum-Resistant Adenocarcinoma of the Lung
por: Wada, Sae, et al.
Publicado: (2012)

Evaluation of Chemotherapeutic Agents
por: Engstrom, W. W.
Publicado: (1949)

Huaier Augmented the Chemotherapeutic Sensitivity of Oxaliplatin via Downregulation of YAP in Hepatocellular Carcinoma
por: Tao, Yuquan, et al.
Publicado: (2018)

Identification of biomarkers predicting the chemotherapeutic outcomes of capecitabine and oxaliplatin in patients with gastric cancer
por: Zhang, Yan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mb5tmng96qjpjpbudccm921bq7